About 2,330 results

ALLMedicine™ Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  822 results

Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with r...
Journal of Thrombosis and Thrombolysis; Beltrami-Moreira M, DeSancho MT

Jan 14th, 2022 - Congenital thrombotic thrombocytopenic purpura (cTTP) is caused by ADAMTS13 mutations and associated with high risk of microvascular thrombosis. A 58 year old female had an ischemic stroke during hormonal fertility, and a TIA a year after. She suf...

Hematology Emergencies in Critically Ill Adults: Benign Hematology.
Chest Spring J, Munshi L

Jan 11th, 2022 - Hematologic conditions (malignant or benign) may progress to acute critical illness requiring prompt recognition and intensive management. In this review, we outline diagnostic considerations and approach to management for intensivists of common b...

Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic pu...
Journal of Thrombosis and Haemostasis : JTH; Kühne L, Kaufeld J et. al.

Jan 10th, 2022 - The anti-VWF nanobody caplacizumab directly prevents the fatal microthrombi formation in immune-mediated thrombotic thrombocytopenic purpura (iTTP), thereby adding a new therapeutic principle to the treatment of this disorder. However, real-world ...

Evaluation of solvent/detergent-treated plasma safety and efficacy in orthotopic liver ...
Transfusion McRae HL, Milito C et. al.

Dec 29th, 2021 - Solvent/detergent-treated, pooled plasma (SDP) is approved for use in orthotopic liver transplantation (OLT) and thrombotic thrombocytopenic purpura (TTP) patients; however, studies evaluating safety and effectiveness of SDP in these populations a...

Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic throm...
Expert Review of Pharmacoeconomics & Outcomes Research; Gil-Rojas Y, Lasalvia P

Dec 15th, 2021 - The objective of the study was to evaluate the costs and benefits of early identification and treatment (within 24 hours of admission) of patients with aTTP in Colombia. A cost-consequence analysis was conducted to evaluate the costs and health ou...

see more →

Drugs  39 results see all →

Clinicaltrials.gov  10 results

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Nov 22nd, 2021 - The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura

Sep 16th, 2021 - The lack of ADAMTS13 is the only biological marker that is specific for aTTP diagnosis8 and the assessment of ADAMTS13 is of clinical importance because it is essential for the rapid differential diagnosis between aTTP and other TMA. Furthermore, ...

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

Nov 18th, 2020 - Background Thrombocytopenia and microangiopathic hemolytic anemia together with a severely deficient ADAMTS13 activity confirm the diagnosis of acute thrombotic thrombocytopenic purpura (TTP). Today two forms of classical TTP are distinguished. Th...

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

May 22nd, 2019 - The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

TTP and aHUS in Complicated Pregnancies

Sep 25th, 2018 - A single site observational study aiming to: (i) Identify cases of previously undiagnosed thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic syndrome (aHUS) in a cohort of women with complicated pregnancies (ii) Characterise the cli...

see more →

News  59 results

Spreading Newfound Treatment Strategies in Hematologic Malignancies in Seattle

Oct 6th, 2021 - We recently traveled to Seattle, California for an OncLive® State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Seattle Cancer Care Alliance provided insight on current and evolving standards of care in leukemia,...

Overview of Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

Apr 2nd, 2021 - Samer Khaled, MD: Hello, and welcome to this OncLive® Peer Exchange® titled Transplant-Associated Thrombotic Microangiopathy, or TA-TMA. TA-TMA remains a difficult complication to address with a high mortality rate and a lack of standard diagnosti...

TMA Management: Agents That Inhibit Endothelial Cell Injury

Apr 2nd, 2021 - Transcript: Vincent T. Ho, MD: Defibrotide has been around for many years. It is the only drug that is currently FDA approved for the treatment of transplant-associated hepatic veno-occlusive disease, which is a condition that also involves en...

Survival Outcomes in HSCT-TMA After Transplant

Apr 2nd, 2021 - Transcript: Vincent T. Ho, MD: Transplant-associated TMA [thrombotic microangiopathy] is a major problem after transplantation. The survival rates in these patients after development of this disease varies in the literature. But in general, fo...

Neoadjuvant Atezolizumab Regimen Slightly Improves pCR in TNBC

Dec 20th, 2020 - Luca Gianni, MD Atezolizumab (Tecentriq) in combination with carboplatin and nab-paclitaxel (Abraxane) did not lead to a statistically significant increase in pathologic complete response (pCR) rate compared with carboplatin/nab-paclitaxel alone ...

see more →

Patient Education  2 results see all →